celecoxib and rivastigmine

celecoxib has been researched along with rivastigmine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Ibrar, A; Khan, I; Saeed, F; Shehzadi, SA	1
Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A	1
Agrawal, R; Assaiya, A; Banerjee, T; Jain, N; Kumar, A; Manivannan, E; Mufti, I; Parmar, HS; Tiwari, S	1

Reviews

2 review(s) available for celecoxib and rivastigmine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery. Bioorganic & medicinal chemistry, 2018, 07-30, Volume: 26, Issue:13 Topics: Aldehyde Reductase; Alkaline Phosphatase; Cholinesterases; Coumarins; Drug Design; Enzymes; Glucosidases; Humans; Molecular Docking Simulation; Monoamine Oxidase	2018

Other Studies

2 other study(ies) available for celecoxib and rivastigmine

Article	Year
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase. European journal of medicinal chemistry, 2019, Apr-01, Volume: 167 Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles	2019
Inhibition of Aβ(1-42)Oligomerization, Fibrillization and Acetylcholinesterase Activity by Some Anti-Inflammatory Drugs: An in vitro Study. Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2017, Volume: 15, Issue:3 Topics: Acetylcholinesterase; Amyloid; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Butylated Hydroxyanisole; Celecoxib; Dexamethasone; Diclofenac; Indomethacin; Methylene Blue; Nitric Oxide; Peptide Fragments; Piroxicam; Rivastigmine; Singlet Oxygen	2017

Article

Year

Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.

European journal of medicinal chemistry, 2019, Apr-01, Volume: 167

Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles

2019

Inhibition of Aβ(1-42)Oligomerization, Fibrillization and Acetylcholinesterase Activity by Some Anti-Inflammatory Drugs: An in vitro Study.

Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2017, Volume: 15, Issue:3

Topics: Acetylcholinesterase; Amyloid; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Butylated Hydroxyanisole; Celecoxib; Dexamethasone; Diclofenac; Indomethacin; Methylene Blue; Nitric Oxide; Peptide Fragments; Piroxicam; Rivastigmine; Singlet Oxygen

2017